Prognostic value of the density of tumor‑infiltrating lymphocytes in colorectal cancer liver metastases

Wang,En; Shibutani,Masatsune; Nagahara,Hisashi; Fukuoka,Tatsunari; Iseki,Yasuhito; Okazaki,Yuki; Kashiwagi,Shinichiro; Tanaka,Hiroaki; Maeda,Kiyoshi

doi:10.3892/ol.2021.13098

Prognostic value of the density of tumor‑infiltrating lymphocytes in colorectal cancer liver metastases

Authors:
- En Wang
- Masatsune Shibutani
- Hisashi Nagahara
- Tatsunari Fukuoka
- Yasuhito Iseki
- Yuki Okazaki
- Shinichiro Kashiwagi
- Hiroaki Tanaka
- Kiyoshi Maeda
View Affiliations

Affiliations: Department of Gastroenterological Surgery, Osaka City University Graduate School of Medicine, Abeno‑ku, Osaka 545‑8585, Japan, Department of Breast and Endocrine Surgery, Osaka City University Graduate School of Medicine, Abeno‑ku, Osaka 545‑8585, Japan, Department of Gastroenterological Surgery, Osaka City General Hospital, Miyakojima-ku, Osaka 534-0021, Japan
Published online on: October 18, 2021 https://doi.org/10.3892/ol.2021.13098
Article Number: 837
Copyright: © Wang et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Tumor‑infiltrating lymphocytes (TILs) have been reported to reflect the anti‑tumor immune status of patients and to be correlated with their prognosis and therapeutic outcomes. However, the characteristics of the local immune status in metastatic tumors is poorly understood, as primary tumors have been the focus in most previous studies. In addition, the local immune status may be influenced by preoperative chemotherapy. The present study aimed therefore to investigate the relationship between the degree of TIL infiltration and the prognosis in patients with curative resection of colorectal cancer liver metastases and to examine the effects of preoperative chemotherapy on the function of immune cells. A total of 108 patients who underwent curative resection of colorectal cancer liver metastases in our department between May 1996 and January 2017 were enrolled in the present study. Peripheral blood samples were obtained within two weeks before surgery. TIL infiltration was evaluated by immunohistochemical staining of surgically resected specimens of liver metastases using anti‑CD8/CD3 antibodies. The mean number of TILs in five different fields was calculated, and patients were classified into a high‑TIL group and a low‑TIL group. Furthermore, patients were divided into three groups as follows: i) A group of patients who did not receive preoperative chemotherapy; ii) a group of patients who received short‑term preoperative chemotherapy for <6 months; and iii) a group of patients who received long‑term preoperative chemotherapy for ≥6 months. The results demonstrated that the density of TILs in colorectal liver metastases was not correlated with the absolute peripheral lymphocyte count in all patients. Furthermore, the degree of CD8⁺TIL infiltration in liver metastases was significantly lower in the recurrence group compared with the recurrence‑free group following hepatectomy. In all patients with colorectal liver metastases, the degree of CD8⁺TIL infiltration was significantly associated with the relapse‑free and overall survival. In patients without preoperative chemotherapy, the degree of CD8⁺TIL infiltration was significantly associated with the relapse‑free survival, and a high CD8+TIL presence tended to have a better effect on the overall survival than a low CD8⁺TIL presence. In the short‑term chemotherapy group, the degree of CD8⁺TIL infiltration was significantly associated with the relapse‑free and overall survival. In the long‑term chemotherapy group, there were no significant differences between the high‑ and low‑ CD8⁺TIL groups in the relapse‑free and overall survival. In contrast to CD8⁺TILs, CD3⁺TILs showed a poor prognostic ability. In summary, the degree of CD8⁺TIL infiltration in colorectal cancer liver metastases may be correlated with patient prognosis. However, in patients who received long‑term chemotherapy before surgery, the degree of TIL infiltration was not necessarily associated with prognosis as the anti‑tumor effects of TILs may decrease. The degree of CD8⁺TIL infiltration may therefore be considered as a useful prognostic factor in patients with colorectal liver metastases, but the prognostic accuracy may decrease in patients who received long‑term chemotherapy.

View Figures

View References

1	World Health Organization (WHO), . WHO report on cancer: setting priorities, investing wisely and providing care for all. World Health Organization; Geneva: 2020
2	Watanabe T, Muro K, Ajioka Y, Hashiguchi Y, Ito Y, Saito Y, Hamaguchi T, Ishida H, Ishiguro M, Ishihara S, et al: Japanese Society for Cancer of the Colon and Rectum (JSCCR) guidelines 2016 for the treatment of colorectal cancer. Int J Clin Oncol. 23:1–34. 2018. View Article : Google Scholar : PubMed/NCBI
3	Niederhuber JE: Colon and rectum cancer. Patterns of spread and implications for workup. Cancer. 71 (Suppl 12):4187–4192. 1993. View Article : Google Scholar : PubMed/NCBI
4	Wakabayashi T, Hibi T, Yoneda G, Iwao Y, Sawada Y, Hoshino H, Uemura S, Ban D, Kudo A, Takemura Y, et al: Predictive model for survival after liver resection for noncolorectal liver metastases in the modern era: A Japanese multicenter analysis. J Hepatobiliary Pancreat Sci. 26:441–448. 2019. View Article : Google Scholar : PubMed/NCBI
5	Zarour LR, Anand S, Billingsley KG, Bisson WH, Cercek A, Clarke MF, Coussens LM, Gast CE, Geltzeiler CB, Hansen L, et al: Colorectal Cancer Liver Metastasis: Evolving Paradigms and Future Directions. Cell Mol Gastroenterol Hepatol. 3:163–173. 2017. View Article : Google Scholar : PubMed/NCBI
6	Abdalla EK, Vauthey JN, Ellis LM, Ellis V, Pollock R, Broglio KR, Hess K and Curley SA: Recurrence and outcomes following hepatic resection, radiofrequency ablation, and combined resection/ablation for colorectal liver metastases. Ann Surg. 239:818–825; discussion 825-827. 2004. View Article : Google Scholar : PubMed/NCBI
7	Kato T, Yasui K, Hirai T, Kanemitsu Y, Mori T, Sugihara K, Mochizuki H and Yamamoto J: Therapeutic results for hepatic metastasis of colorectal cancer with special reference to effectiveness of hepatectomy: Analysis of prognostic factors for 763 cases recorded at 18 institutions. Dis Colon Rectum. 46 (Suppl 10):S22–S31. 2003.PubMed/NCBI
8	Gooden MJ, de Bock GH, Leffers N, Daemen T and Nijman HW: The prognostic influence of tumour-infiltrating lymphocytes in cancer: A systematic review with meta-analysis. Br J Cancer. 105:93–103. 2011. View Article : Google Scholar : PubMed/NCBI
9	Zhang D, He W, Wu C, Tan Y, He Y, Xu B, Chen L, Li Q and Jiang J: Scoring System for Tumor-Infiltrating Lymphocytes and Its Prognostic Value for Gastric Cancer. Front Immunol. 10:71. 2019. View Article : Google Scholar : PubMed/NCBI
10	Ropponen KM, Eskelinen MJ, Lipponen PK, Alhava E and Kosma V-M: Prognostic value of tumour-infiltrating lymphocytes (TILs) in colorectal cancer. J Pathol. 182:318–324. 1997. View Article : Google Scholar : PubMed/NCBI
11	Canna K, McArdle PA, McMillan DC, McNicol AM, Smith GW, McKee RF and McArdle CS: The relationship between tumour T-lymphocyte infiltration, the systemic inflammatory response and survival in patients undergoing curative resection for colorectal cancer. Br J Cancer. 92:651–654. 2005. View Article : Google Scholar : PubMed/NCBI
12	Mei Z, Liu Y, Liu C, Cui A, Liang Z, Wang G, Peng H, Cui L and Li C: Tumour-infiltrating inflammation and prognosis in colorectal cancer: Systematic review and meta-analysis. Br J Cancer. 110:1595–1605. 2014. View Article : Google Scholar : PubMed/NCBI
13	Shibutani M, Maeda K, Nagahara H, Fukuoka T, Iseki Y, Matsutani S, Kashiwagi S, Tanaka H, Hirakawa K and Ohira M: Tumor-infiltrating Lymphocytes Predict the Chemotherapeutic Outcomes in Patients with Stage IV Colorectal Cancer. In Vivo. 32:151–158. 2018.PubMed/NCBI
14	Matsutani S, Shibutani M, Maeda K, Nagahara H, Fukuoka T, Nakao S, Hirakawa K and Ohira M: Significance of tumor-infiltrating lymphocytes before and after neoadjuvant therapy for rectal cancer. Cancer Sci. 109:966–979. 2018. View Article : Google Scholar : PubMed/NCBI
15	Teng F, Mu D, Meng X, Kong L, Zhu H, Liu S, Zhang J and Yu J: Tumor infiltrating lymphocytes (TILs) before and after neoadjuvant chemoradiotherapy and its clinical utility for rectal cancer. Am J Cancer Res. 5:2064–2074. 2015.PubMed/NCBI
16	Anitei MG, Zeitoun G, Mlecnik B, Marliot F, Haicheur N, Todosi AM, Kirilovsky A, Lagorce C, Bindea G, Ferariu D, et al: Prognostic and predictive values of the immunoscore in patients with rectal cancer. Clin Cancer Res. 20:1891–1899. 2014. View Article : Google Scholar : PubMed/NCBI
17	Lee WS, Kang M, Baek JH, Lee JI and Ha SY: Clinical impact of tumor-infiltrating lymphocytes for survival in curatively resected stage IV colon cancer with isolated liver or lung metastasis. Ann Surg Oncol. 20:697–702. 2013. View Article : Google Scholar : PubMed/NCBI
18	Shibutani M, Maeda K, Nagahara H, Fukuoka T, Matsutani S, Kashiwagi S, Tanaka H, Hirakawa K and Ohira M: A comparison of the local immune status between the primary and metastatic tumor in colorectal cancer: A retrospective study. BMC Cancer. 18:3712018. View Article : Google Scholar : PubMed/NCBI
19	Kito A, Tanaka K, Fujimaki H, Nakazawa M, Togo S, Minami M and Shimada H: Tumor doubling time and local immune response to hepatic metastases from colorectal cancer. J Surg Oncol. 96:525–533. 2007. View Article : Google Scholar : PubMed/NCBI
20	Wu Y, Deng Z, Wang H, Ma W, Zhou C and Zhang S: Repeated cycles of 5-fluorouracil chemotherapy impaired anti-tumor functions of cytotoxic T cells in a CT26 tumor-bearing mouse model. BMC Immunol. 17:292016. View Article : Google Scholar : PubMed/NCBI
21	Adam R, de Gramont A, Figueras J, Kokudo N, Kunstlinger F, Loyer E, Poston G, Rougier P, Rubbia-Brandt L, Sobrero A, et al: Managing synchronous liver metastases from colorectal cancer: A multidisciplinary international consensus. Cancer Treat Rev. 41:729–741. 2015. View Article : Google Scholar : PubMed/NCBI
22	Galon J, Costes A, Sanchez-Cabo F, Kirilovsky A, Mlecnik B, Lagorce-Pagès C, Tosolini M, Camus M, Berger A, Wind P, et al: Type, density, and location of immune cells within human colorectal tumors predict clinical outcome. Science. 313:1960–1964. 2006. View Article : Google Scholar : PubMed/NCBI
23	Fridman WH, Pagès F, Sautès-Fridman C and Galon J: The immune contexture in human tumours: Impact on clinical outcome. Nat Rev Cancer. 12:298–306. 2012. View Article : Google Scholar : PubMed/NCBI
24	Galon J, Angell HK, Bedognetti D and Marincola FM: The continuum of cancer immunosurveillance: Prognostic, predictive, and mechanistic signatures. Immunity. 39:11–26. 2013. View Article : Google Scholar : PubMed/NCBI
25	Pagès F, Kirilovsky A, Mlecnik B, Asslaber M, Tosolini M, Bindea G, Lagorce C, Wind P, Marliot F, Bruneval P, et al: In situ cytotoxic and memory T cells predict outcome in patients with early-stage colorectal cancer. J Clin Oncol. 27:5944–5951. 2009. View Article : Google Scholar : PubMed/NCBI
26	Eriksen AC, Sørensen FB, Lindebjerg J, Hager H, dePont Christensen R, Kjær-Frifeldt S and Hansen TF: The Prognostic Value of Tumor-Infiltrating lymphocytes in Stage II Colon Cancer. A Nationwide Population-Based Study. Transl Oncol. 11:979–987. 2018. View Article : Google Scholar : PubMed/NCBI
27	Halama N, Michel S, Kloor M, Zoernig I, Pommerencke T, von Knebel Doeberitz M, Schirmacher P, Weitz J, Grabe N and Jäger D: The localization and density of immune cells in primary tumors of human metastatic colorectal cancer shows an association with response to chemotherapy. Cancer Immun. 9:12009.PubMed/NCBI
28	Katz SC, Pillarisetty V, Bamboat ZM, Shia J, Hedvat C, Gonen M, Jarnagin W, Fong Y, Blumgart L, D'Angelica M, et al: T cell infiltrate predicts long-term survival following resection of colorectal cancer liver metastases. Ann Surg Oncol. 16:2524–2530. 2009. View Article : Google Scholar : PubMed/NCBI
29	Boon T, Cerottini JC, Van den Eynde B, van der Bruggen P and Van Pel A: Tumor antigens recognized by T lymphocytes. Annu Rev Immunol. 12:337–365. 1994. View Article : Google Scholar : PubMed/NCBI
30	Cullen SP, Brunet M and Martin SJ: Granzymes in cancer and immunity. Cell Death Differ. 17:616–623. 2010. View Article : Google Scholar : PubMed/NCBI
31	Medema JP, de Jong J, Peltenburg LT, Verdegaal EM, Gorter A, Bres SA, Franken KL, Hahne M, Albar JP, Melief CJ, et al: Blockade of the granzyme B/perforin pathway through overexpression of the serine protease inhibitor PI-9/SPI-6 constitutes a mechanism for immune escape by tumors. Proc Natl Acad Sci USA. 98:11515–11520. 2001. View Article : Google Scholar : PubMed/NCBI
32	Liu L, Zhao L, Yang Y, Gao J, Hu C, Guo B and Zhu B: Cytotoxic chemotherapy reduces T cell trafficking to the spleen by downregulating the expression of C-C motif chemokine ligand 21 and C-C motif chemokine ligand 19. Oncol Lett. 16:5013–5019. 2018.PubMed/NCBI
33	Mackall CL: T-cell immunodeficiency following cytotoxic antineoplastic therapy: A review. Stem Cells. 18:10–18. 2000. View Article : Google Scholar : PubMed/NCBI
34	Zhang P, Ma Y, Lv C, Huang M, Li M, Dong B, Liu X, An G, Zhang W, Zhang J, et al: Upregulation of programmed cell death ligand 1 promotes resistance response in non-small-cell lung cancer patients treated with neo-adjuvant chemotherapy. Cancer Sci. 107:1563–1571. 2016. View Article : Google Scholar : PubMed/NCBI
35	Guo L, Song P, Xue X, Guo C, Han L, Fang Q, Ying J, Gao S and Li W: Variation of Programmed Death Ligand 1 Expression After Platinum-based Neoadjuvant Chemotherapy in Lung Cancer. J Immunother. 42:215–220. 2019. View Article : Google Scholar : PubMed/NCBI
36	Khairallah AS, Genestie C, Auguste A and Leary A: Impact of neoadjuvant chemotherapy on the immune microenvironment in advanced epithelial ovarian cancer: Prognostic and therapeutic implications. Int J Cancer. 143:8–15. 2018. View Article : Google Scholar : PubMed/NCBI
37	Xiao B, Peng J, Wang Y, Deng Y, Ou Q, Wu X, Lin J, Pan Z and Zhang L: Prognostic value of tumor infiltrating lymphocytes combined with PD-L1 expression for patients with solitary colorectal cancer liver metastasis. Ann Transl Med. 8:12212020. View Article : Google Scholar : PubMed/NCBI
38	Thompson ED, Zahurak M, Murphy A, Cornish T, Cuka N, Abdelfatah E, Yang S, Duncan M, Ahuja N, Taube JM, et al: Patterns of PD-L1 expression and CD8 T cell infiltration in gastric adenocarcinomas and associated immune stroma. Gut. 66:794–801. 2017. View Article : Google Scholar : PubMed/NCBI
39	Joyce JA and Fearon DT: T cell exclusion, immune privilege, and the tumor microenvironment. Science. 348:74–80. 2015. View Article : Google Scholar : PubMed/NCBI
40	Salmon H, Franciszkiewicz K, Damotte D, Dieu-Nosjean MC, Validire P, Trautmann A, Mami-Chouaib F and Donnadieu E: Matrix architecture defines the preferential localization and migration of T cells into the stroma of human lung tumors. J Clin Invest. 122:899–910. 2012. View Article : Google Scholar : PubMed/NCBI
41	Slaney CY, Kershaw MH and Darcy PK: Trafficking of T cells into tumors. Cancer Res. 74:7168–7174. 2014. View Article : Google Scholar : PubMed/NCBI